Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Celcuity

Explore full profile

Precision oncology therapies guided by companion diagnostics

Plymouth, United StatesFounded 2012Biotech & Life Sciences
Valuation $4.09B Market cap · 2026
Revenue $39M Latest reported FY

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of various solid tumor indications. The company operates in the oncology market, with a business model centered on its proprietary CELsignia platform. This platform is a functional cellular analysis tool that aims to identify new cancer subtypes and predict the effectiveness of targeted therapies for individual patients, thereby enabling a more personalized approach to cancer treatment.

The company's primary clients are oncologists and clinicians who are seeking more effective treatment options for their patients. By developing companion diagnostics alongside its therapeutic candidates, Celcuity aims to ensure that its drugs are prescribed to the patients who are most likely to benefit. The company is publicly traded and is currently advancing its lead drug candidate, Gedatolisib, through clinical trials for the treatment of breast cancer. Its revenue generation will be dependent on the successful clinical development, regulatory approval, and commercialization of its therapeutic and diagnostic products.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2012
Headquarters
Plymouth, United States
Listing
IPO 2017
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierColt$25–100M revenue

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Brightstone Venture Capital

Series B and later13 investors entered at this stage

  • Venrock Healthcare Capital Partners
  • RA Capital Management
  • Soleus Capital
  • NEA
  • Commodore Capital
  • Oxford Finance
  • Innovatus Capital Partners
  • Eventide Asset Management
  • Driehaus Capital Management
  • Blue Owl Capital
  • BVF Partners
  • Vivo Capital
  • Samlyn Capital
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99.3%
🇵🇱 Poland0.7%
2 countries shown
Web traffic by country
23K monthly visits
across markets
🇺🇸 United States73%
🏳️ Korea10.9%
🏳️ Republic of5.2%
🇮🇳 India4.8%
🇬🇧 United Kingdom3%
Top 5 markets shown

Patents

Estimated portfolio value
$9M

9 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Celcuity on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Celcuity on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.